Field & Main Bank Acquires 7,985 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Field & Main Bank boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 63.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,591 shares of the biopharmaceutical company's stock after buying an additional 7,985 shares during the quarter. Field & Main Bank's holdings in Bristol Myers Squibb were worth $1,256,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Wealthspire Advisors LLC raised its holdings in Bristol Myers Squibb by 0.6% in the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after purchasing an additional 170 shares in the last quarter. Bedel Financial Consulting Inc. increased its position in shares of Bristol Myers Squibb by 3.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock valued at $340,000 after buying an additional 175 shares during the period. King Wealth Management Group raised its stake in Bristol Myers Squibb by 2.6% in the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock worth $413,000 after buying an additional 182 shares in the last quarter. Thoroughbred Financial Services LLC lifted its holdings in Bristol Myers Squibb by 1.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 190 shares during the period. Finally, Marcum Wealth LLC boosted its position in Bristol Myers Squibb by 1.0% during the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock valued at $1,177,000 after acquiring an additional 193 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on BMY. Jefferies Financial Group lowered their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Argus raised Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. UBS Group lowered their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $58.00.

Insiders Place Their Bets

In other news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.07% of the stock is currently owned by insiders.

Bristol Myers Squibb Trading Up 0.2%

Shares of NYSE:BMY opened at $47.04 on Wednesday. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. Bristol Myers Squibb Company has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a market cap of $95.72 billion, a P/E ratio of 17.62, a PEG ratio of 1.39 and a beta of 0.38. The stock's fifty day moving average price is $48.06 and its 200-day moving average price is $54.16.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the prior year, the business earned ($4.40) EPS. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.27%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is currently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.